The technical machinery behind the analysis was rigorous. The researchers followed the PRISMA 2020 reporting guidelines and searched six major databases, including PubMed, Scopus, Embase, Web of Science, the Cochrane Library, and African Journals Online, for studies reporting World Health Organization-defined treatment outcomes among patients with drug-resistant tuberculosis in Cameroon. Rather than relying on simple pooled proportions, the team employed random-effects meta-analyses using generalized linear mixed models with logit transformation, a statistically robust approach that better accommodates the variation inherent in observational studies. Heterogeneity across studies was quantified using the I-squared statistic, and the authors conducted both publication bias assessments and sensitivity analyses to test the stability of their findings. The review was prospectively registered under number CRD420261404490.

The headline numbers tell a nuanced story. Across fourteen reports encompassing 2,351 participants, the pooled mortality rate was 6.8 percent, with a 95 percent confidence interval of 4.7 to 9.7 percent and moderate heterogeneity of 58.1 percent. Loss to follow-up, a persistent scourge of long tuberculosis treatment courses, stood at 4.1 percent across twelve reports covering 2,244 participants. Treatment failure, the outcome that most directly signals regimens not working, was estimated at 4.2 percent, though the striking heterogeneity of 93.3 percent across thirteen reports and 2,050 participants suggests this figure should be interpreted with considerable caution. The pooled treatment success rate, drawing on thirteen reports and 2,146 participants, was 74.2 percent, with a wide confidence interval of 60.4 to 84.4 percent and high heterogeneity of 88.1 percent.

That heterogeneity is not a mere statistical footnote. It reflects the reality that the included studies, most of which were observational cohorts, spanned nearly a quarter of a century of evolving treatment paradigms, from the era of injectable agent-based regimens to the early adoption of shorter and all-oral protocols. Patients treated in 1998 faced radically different drug combinations, diagnostic capacity, and HIV care landscapes than those treated in 2022. The very high I-squared values for treatment failure and treatment success mean the true underlying rates likely vary substantially across settings, patient populations, and time periods within Cameroon, and the pooled estimates should be read as a national synthesis rather than a single universal figure.

Perhaps the most clinically striking findings concern adverse drug events. Among patients with multidrug-resistant tuberculosis, the pooled prevalence of adverse drug events was a remarkable 70.8 percent, based on three studies with 251 participants, though the confidence interval of 40.2 to 89.7 percent is wide. Ototoxicity, damage to the inner ear that can cause permanent hearing loss and balance problems, was the most common event at 41.9 percent, followed closely by gastrointestinal disorders at 40.9 percent. These figures underscore the brutal toll that second-line tuberculosis therapy has historically exacted on patients. Aminoglycoside injectables, long a backbone of multidrug-resistant tuberculosis treatment, are notorious for cochlear and vestibular toxicity, and the high ototoxicity rate in this review is consistent with global experience with injectable-containing regimens.

The predictors of unfavorable outcomes tell an equally important story. HIV co-infection was significantly associated with unfavorable treatment outcomes, with a pooled odds ratio of 2.76 and a 95 percent confidence interval of 1.95 to 3.93 across six studies. In practical terms, patients living with HIV who contracted drug-resistant tuberculosis had nearly three times the odds of dying, failing treatment, being lost to follow-up, or otherwise not achieving cure compared with HIV-negative patients. This finding carries particular weight in Cameroon, where HIV prevalence remains substantial and tuberculosis is the leading cause of death among people living with HIV. The biological rationale is clear: immunosuppression impairs the body’s ability to contain infection, drug interactions between antiretrovirals and second-line tuberculosis drugs complicate therapy, and overlapping toxicities can force regimen modifications that undermine efficacy.

Male sex emerged as the second significant predictor, with men showing 73 percent higher odds of unfavorable outcomes than women, based on a pooled odds ratio of 1.73 across five studies. This pattern echoes a well-documented global phenomenon in tuberculosis care. Men consistently account for the majority of tuberculosis cases worldwide, are more likely to delay seeking care, face greater barriers to adherence including occupational and mobility constraints, and experience worse retention in care. In the context of a drug-resistant disease requiring eighteen to twenty months of therapy under older regimens, these structural and behavioral disadvantages compound into measurably worse outcomes.

The authors’ conclusions point toward concrete solutions. They argue that strengthening pharmacovigilance, the systematic detection and monitoring of adverse drug events, is essential given that more than two-thirds of multidrug-resistant tuberculosis patients experienced significant drug toxicity. Early detection of hearing loss, for example, allows clinicians to modify regimens before irreversible damage occurs, and active adverse event monitoring improves patient retention. Equally critical, they emphasize, is the integration of tuberculosis and HIV services, ensuring that co-infected patients receive coordinated antiretroviral therapy and tuberculosis treatment rather than fragmented care that increases mortality risk.

The most consequential recommendation, however, concerns the transition to all-oral regimens. The data synthesized in this review largely reflect the era of injectable-containing therapy, with its attendant ototoxicity and injection-site complications. Newer all-oral short-course regimens built around bedaquiline and other modern drugs have demonstrated superior efficacy and dramatically better tolerability in global trials and programmatic rollouts. For Cameroon, implementing these regimens nationwide would address several of the review’s findings simultaneously: reducing the catastrophic adverse event burden, potentially improving treatment success toward the 85 percent national target, and making the long treatment journey more humane for patients.

The study is not without limitations inherent to its design. The reliance on observational cohort studies, the wide confidence intervals around several estimates, and the substantial heterogeneity all counsel careful interpretation, and the authors themselves acknowledge these constraints. Yet the value of this work lies precisely in its synthesis: for the first time, Cameroon has a nationally representative, statistically rigorous estimate of how its drug-resistant tuberculosis program is performing. With mortality near 7 percent, one in twenty patients lost to follow-up, and one in four not achieving cure, the gap between current reality and national ambitions is now quantified. Closing that gap, the review makes clear, will require not just better drugs but better systems: vigilant drug safety monitoring, seamless HIV integration, and the political commitment to bring modern, all-oral therapy to every patient who needs it.

Subject of Research: Treatment outcomes of drug-resistant tuberculosis in Cameroon

Article Title: Treatment outcomes of drug-resistant Mycobacterium tuberculosis disease in Cameroon: a systematic review and meta-analysis

Article References: Cheuyem, F. Z. L., Touko, A. D., Achangwa, C., Tchamani, R., Otsali, R. K. N., Mapouo, C. J. K., & Temgoua, M. N. (2026). Treatment outcomes of drug-resistant Mycobacterium tuberculosis disease in Cameroon: a systematic review and meta-analysis. BMC Infectious Diseases. https://doi.org/10.1186/s12879-026-14591-x

Image Credits: AI Generated

DOI: 10.1186/s12879-026-14591-x

Keywords: drug-resistant tuberculosis, Mycobacterium tuberculosis, Cameroon, systematic review, meta-analysis, treatment outcomes, HIV co-infection, adverse drug events, ototoxicity, pharmacovigilance, all-oral regimens, treatment success rate

Oxazolidinones occupy a special place in modern medicinal chemistry. The five-membered ring, containing both a nitrogen and an oxygen atom adjacent to a carbonyl, appears in approved antibiotics and in countless molecules moving through drug discovery pipelines. Of particular urgency are the 5-(S)-aminomethyl oxazolidinones, scaffolds central to next-generation antibiotics designed to combat multidrug-resistant and extensively drug-resistant strains of Mycobacterium tuberculosis, the pathogen behind one of the deadliest infectious diseases on Earth. As resistance spreads, the demand for efficient ways to assemble these rings has grown correspondingly sharper.

The trouble, historically, has been chirality. Molecules like oxazolidinones are three-dimensional objects, and their biological activity depends exquisitely on the handedness of their stereocentres. Conventional synthetic routes have leaned on the so-called chiral pool strategy, in which enantiopure amino alcohols harvested from natural sources serve as the key starting intermediates. That approach works, but it constrains chemists to the structural inventory of nature and demands lengthy sequences of functional group manipulations. Many methods exist to set the stereocentre at the 4-position of the ring, alpha to nitrogen, yet strategies for installing the 5-stereocentre, alpha to oxygen, have remained underdeveloped, leaving a stubborn gap in the synthetic toolbox.

The Caltech and Pittsburgh teams closed that gap with a two-stage reaction sequence performed by a single engineered enzyme. The cascade begins with aziridination, a transformation in which a nitrogen atom, delivered as a nitrene, is inserted across a carbon-carbon double bond to form a three-membered aziridine ring. The enzyme then guides a ring expansion of that strained intermediate, and the aziridine rearranges into the five-membered oxazolidinone. The result is a direct, enantioselective synthesis of clinically relevant and discovery-stage oxazolidinones starting from the simplest possible feedstocks: plain alkenes.

The choice of catalyst reflects a larger trend in synthetic biology. Haemproteins, enzymes built around an iron-containing porphyrin cofactor, have emerged in recent years as remarkably tunable platforms for carbene and nitrene transfer chemistry, reactions that no natural enzyme performs natively. Under the directed evolution methods pioneered in Arnold’s laboratory, researchers mutate and screen these proteins iteratively until the active site, originally shaped by evolution for tasks such as oxygen insertion, learn to conduct entirely new chemical transformations with high selectivity. In the new work, mutations introduced through directed evolution proved to be the decisive factor in controlling which mirror-image product the reaction delivers.

What makes the achievement stand out within the biocatalysis community is the class of alkene substrates involved. Until now, haemprotein-catalysed nitrene transfer has been largely restricted to conjugated systems such as styrenes, alkenes whose electronic character makes them reactive and easy to control. Unactivated alkenes, the saturated, electronically inert double bonds that pepper the structures of fats, terpenes, and countless pharmaceutical precursors, have resisted this chemistry. By extending nitrene transfer to these unactivated substrates, the new work substantially broadens the reach of enzymatic nitrene chemistry and opens a much wider swath of chemical space to biocatalytic functionalisation.

Behind the laboratory results lies a computational story. The team carried out detailed computational analysis of the reaction mechanism and found that the key mutations installed during directed evolution are directly responsible for the enantioselective formation of the products. In other words, the protein scaffold does not merely accelerate the reaction; specific amino acid substitutions sculpt the active site geometry so that the aziridination and ring expansion proceed with the precise three-dimensional outcome needed for the drug-like scaffold. This mechanistic understanding, developed jointly with Liu’s computational group at Pittsburgh, illustrates how theory and laboratory evolution now reinforce one another in modern enzyme design.

The practical implications are considerable. Because the cascade starts from simple alkenes and delivers enantioenriched oxazolidinones directly, it offers medicinal chemists a shorter, more modular path to analogues of clinically validated antibiotic scaffolds. Speeding access to structural variants matters enormously in anti-infective research, where teams must explore hundreds of derivative molecules to optimise potency, safety, and pharmacokinetics before a candidate can enter development. A route that removes the dependence on chiral-pool amino alcohols and sets the difficult 5-stereocentre in a single enzymatic operation could meaningfully compress discovery timelines for drugs aimed at resistant tuberculosis and beyond.

The study also adds a chapter to the broader narrative of enzyme engineering as a general-purpose tool for chemistry. Over the past two decades, the Arnold laboratory and others have shown that haemproteins can be reprogrammed to catalyse reactions absent from biology, including cyclopropanation, silicon-carbon bond formation, and a widening repertoire of nitrogen-transfer chemistry. Each extension of this platform challenges the traditional boundary between biological and abiological synthesis. The direct construction of oxazolidinone rings from unactivated alkenes now joins that list, and it does so with an added mechanistic account of how engineered mutations translate into stereochemical control.

For a field racing against the spread of antimicrobial resistance, the work carries both immediate and long-term significance. In the near term, the biocatalytic cascade provides a validated route to the exact scaffolds needed for the next generation of tuberculosis therapeutics. Over the longer term, the demonstration that engineered haemproteins can tame unactivated alkenes in enantioselective nitrene transfer suggests that many other transformations once considered the exclusive province of transition-metal catalysis may fall within reach of programmed biology. As the authors note, the chemistry was peer-reviewed and accepted by Nature, and while the published version is an early-release article subject to further editorial refinement, its conclusions are citable and carry a permanent digital identifier, marking a milestone that synthetic chemists and drug hunters alike will be watching closely.

Subject of Research: Biocatalytic enantioselective synthesis of chiral oxazolidinones from unactivated alkenes using engineered haemproteins

Article Title: Chiral oxazolidinones via biocatalytic aziridination of unactivated alkenes

Article References: Li, Z.-Q., Hanley, D., Zhang, Y., Xie, P.-P., Wu, S. J., Qin, Z.-Y., Zhang, C., Alfonzo, E., Li, F.-Z., Brinkman-Chen, S., Liu, P., & Arnold, F. H. (2026). Chiral oxazolidinones via biocatalytic aziridination of unactivated alkenes. Nature. https://doi.org/10.1038/s41586-026-11169-0

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11169-0

Keywords: biocatalysis, oxazolidinones, aziridination, nitrene transfer, directed evolution, haemproteins, antibiotics, tuberculosis, enantioselectivity, unactivated alkenes, enzyme engineering, drug discovery

Mycobacterium tuberculosis, the bacterium responsible for tuberculosis, is an obligate human pathogen, meaning it cannot complete its life cycle outside of people. Its continued existence as a species therefore depends entirely on its ability to spread from one host to another, which it accomplishes when infected individuals release bacteria-laden aerosol droplets into the air through coughing, speaking, or breathing. Yet despite the obvious centrality of transmission to the pathogen’s biology, scientists have lacked detailed knowledge of the specific traits that support it. This gap is notable given the scale of the disease: tuberculosis remains one of the deadliest infectious diseases in the world, killing well over a million people each year, and the rise of drug-resistant strains has complicated control efforts in many countries. The new study addresses the transmission gap by focusing on a physical challenge the bacteria inevitably face during spread: desiccation, or drying out, which occurs as aerosol droplets shrink and evaporate in the air.

The research team, led by Christopher D. Brown and Kyu Y. Rhee of Weill Cornell Medicine along with collaborators including Brendon M. Lee, Hannah M. Liu, Amy M. Wu, and structural biologists Seth A. Darst and Elizabeth A. Campbell of The Rockefeller University, designed a laboratory system to mimic this environmental stress. They mounted M. tuberculosis atop a filter platform and exposed the bacteria to varying degrees of humidity, allowing them to model the drying that aerosolized bacteria would experience in the real world. By then rehydrating the samples, the researchers could study not only how the bacteria respond to drying but also how they recover when moisture returns, a scenario that mirrors what happens when droplets are inhaled and reach the warm, moist environment of a new host’s airways. The approach gave the team a controlled, repeatable way to isolate a single transmission-associated stress, something that is nearly impossible to do in studies of naturally transmitted infections, where the conditions of spread cannot be directly observed.

Using transcriptomic analysis, which measures the activity of thousands of genes simultaneously, and metabolomic profiling, which captures the chemical state of cellular metabolism, the researchers charted the molecular consequences of desiccation and rehydration. The results were striking. Dried bacteria showed elevated levels of oxidative stress, a condition in which reactive molecules damage cellular components. Consistent with that stress, the team detected increased oxidative damage and, critically, an accumulation of double-stranded DNA breaks, among the most dangerous forms of genetic injury a cell can sustain. Double-stranded breaks sever both strands of the DNA helix at once, and if left unrepaired they can be lethal to the cell. In response, the bacteria activated DNA repair programs, indicating that the ability to mend a damaged genome is required for survival through the drying and rehydration cycle.

Among the genes whose expression increased during desiccation was mfd, which encodes a transcription-coupled repair factor. Mfd is a protein that patrols genes as they are being transcribed, flagging DNA damage encountered by the transcription machinery and recruiting repair enzymes to those sites. Because actively transcribed genes are particularly vulnerable to damage, and because unrepaired lesions in transcribed regions can stall the enzymes that read DNA into RNA, transcription-coupled repair provides an efficient first line of defense. Its upregulation under dry conditions suggested that Mfd might play a particularly important role in helping M. tuberculosis cope with the genomic insults of transmission. What the researchers discovered next, however, went beyond simple repair and touched directly on one of the most consequential issues in tuberculosis treatment: antibiotic resistance.

Some mutations in rpoB, the gene encoding a subunit of bacterial RNA polymerase, confer resistance to rifampin, a cornerstone drug of standard tuberculosis therapy. Rifampin is central to the standard multidrug regimen, and resistance to it is a key trigger for classifying a case as multidrug-resistant tuberculosis. These resistance mutations, while advantageous in the presence of the antibiotic, often carry a fitness cost, meaning that bacteria bearing them may grow or survive less well than drug-susceptible counterparts under normal conditions. The team found that mfd expression buffered this fitness cost for specific resistance-conferring rpoB mutations. In other words, the very repair factor induced by the stresses of drying appeared to mask the biological disadvantages that rifampin-resistance mutations would otherwise impose, allowing resistant bacteria to persist more effectively.

To test this idea in a transmission-relevant setting, the researchers silenced mfd during aerosolization of the bacteria. The result was highly specific: strains carrying S450L, the most common rifampin resistance allele found in clinical settings, were disproportionately impaired in their ability to survive the aerosolization process when mfd was absent, while the survival of other strains was less affected. This experiment linked the environmental stress of transmission directly to the differential survival of drug-resistant bacteria, suggesting that the physical journey between hosts is not a neutral event for resistant mutants but a selective filter in which Mfd plays a decisive role.

The epidemiological significance of this laboratory finding was reinforced by an analysis of whole-genome sequences from 51,229 clinically circulating strains of M. tuberculosis. This large-scale survey of real-world bacterial populations provided supporting evidence that the interplay between desiccation responses, DNA repair, and resistance mutations observed in the laboratory is reflected in the patterns of strains actually spreading among patients. Whole-genome sequencing has increasingly been used to track tuberculosis outbreaks and map the spread of resistant lineages, and datasets of this size allow researchers to test whether mechanisms discovered at the bench leave detectable signatures in natural populations. While the study does not establish that desiccation is the sole or even primary driver of rifampin resistance in the clinic, the consistency between the mechanistic experiments and the population-level data strengthens the argument that transmission-associated biology matters for resistance.

Taken together, the studies suggest a provocative reframing of how antibiotic resistance may arise and spread in tuberculosis. Desiccation-induced DNA damage during the generation of aerosol droplets may act as a source of genetic diversification, generating mutations that can, under the right circumstances, potentiate antibiotic resistance. At the same time, the upregulation of Mfd may allow bacteria that have already acquired resistance mutations to survive the rigors of transmission that would otherwise cull them. In this model, the act of spreading between hosts, rather than merely serving as a conduit for pre-existing resistant strains, actively participates in shaping the genetic landscape of the pathogen population. Transmission becomes a bottleneck with evolutionary consequences: only bacteria equipped to withstand drying, and to repair the damage drying causes, pass through it successfully.

The work builds on decades of research into DNA repair systems in bacteria. Mfd-dependent transcription-coupled repair is among the most evolutionarily conserved bacterial repair pathways, and it has been studied primarily in model organisms such as Escherichia coli, where it is known to promote both accurate repair and, in some contexts, mutagenesis. That dual character is relevant here: a repair pathway that generates or tolerates mutation while preserving survival can, under antibiotic pressure, inadvertently favor the emergence of resistant variants. The new findings add an ecological and epidemiological dimension to this basic biology, connecting a housekeeping molecular function to the population dynamics of a global pathogen under a stress condition, drying, that is inseparable from how the pathogen moves through the world.

The implications extend to public health strategy. Rifampin-resistant tuberculosis, including multidrug-resistant forms of the disease, requires longer, more toxic, and more expensive treatment regimens, and the continued emergence of resistance threatens the gains made against the epidemic over recent decades. If the biology of transmission contributes to the survival and spread of resistant strains, then interventions that alter transmission conditions, or approaches that target the DNA damage response itself, could in principle complement existing antibiotic strategies. Such strategies would sit alongside established tools such as rapid molecular diagnostics that detect rifampin resistance, airborne infection control in health facilities, and preventive therapy for exposed contacts. The study’s authors suggest that transmission-associated desiccation-induced DNA damage should be considered a potential source of genetic diversification that can potentiate antibiotic resistance, a conclusion that reframes transmission as a bottleneck with evolutionary consequences rather than a passive relay.

Several limitations and open questions remain. The laboratory system used filter-mounted bacteria exposed to controlled humidity, which approximates but does not fully reproduce the complex physical environment of a real aerosol droplet traveling between hosts, where factors such as droplet composition, temperature, light exposure, and air currents all vary. The findings concern a defined set of rpoB mutations, with S450L as the focal allele, and the extent to which Mfd buffers the costs of other resistance mutations, or of resistance to drugs other than rifampin, awaits further study. The epidemiological analysis, while large, is correlational in nature and cannot by itself prove causation. Nonetheless, by identifying a concrete molecular mechanism, Mfd-mediated buffering of resistance-mutation costs during a transmission-relevant stress, and by validating it against a large clinical dataset, the study provides a credible framework for future investigations into how the environment between hosts shapes the evolution of one of humanity’s oldest pathogens.

Future work is likely to explore whether other repair factors contribute to survival during desiccation, whether the DNA damage generated during drying produces specific mutational signatures detectable in circulating strains, and whether pharmacological or environmental interventions could disrupt the desiccation-repair-resistance axis. Answering those questions could help determine whether targeting Mfd or the broader DNA damage response is a realistic avenue for new tuberculosis therapeutics. For now, the study stands as a reminder that the life of a pathogen between its hosts is not a dormant interlude but an active, stressful, and evolutionarily consequential phase of its existence, one that may quietly influence the trajectory of drug resistance worldwide.